Process for the preparation of (r)-pramipexole
AssigneeDipharma S.p.A.
InventorsPietro ALLEGRINI, Gabriele Razzetti, Vittorio Lucchini
Life of this patent
Estimating the term…
Abstract
The invention relates to a novel process for the preparation of (R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, or a salt thereof.
Claims16
Process for the preparation of a compound of formula (I), in a solid state thereof, or a salt thereof, as the single (R) enantiomer,
- comprising alkylating a compound of formula (II), as the single (R) enantiomer,
- wherein Ra is a free or protected amino group, R3 is hydrogen or a R4—O—CO— group, wherein R4 is a straight or branched C1-C4 alkyl, to obtain a compound of formula (V)
- wherein Ra and R3 are as defined above, and, if necessary, removing the primary amino-protecting group and/or the R4—O—CO— group from the secondary amino group, and/or, if the case, converting a compound of formula (I) into a salt thereof, and/or, if the case, converting a salt of a compound of formula (I) into the free compound,
- characterized in that:
- a) a compound of formula (II), as single (R) enantiomer, or a salt thereof,
- wherein Ra is a protected amino group and R3 is as defined above, is prepared by rearrangement of a compound of formula (III), or a salt thereof, as single (R) enantiomer,
- wherein R is a protected amino group;
- via formation of isocyanate, and subsequent addition of a nucleophilic solvent or subsequent quenching in water in the presence of an acid;
- or
- b) a compound of formula (II), as single (R) enantiomer, or a salt thereof,
- wherein Ra is a free amino group and R3 is hydrogen;
- is prepared by rearrangement of a compound of formula (III), or a salt thereof, as single (R) enantiomer, as defined above;
- via formation of isocyanate, and subsequent addition of water, to obtain a compound of formula (IV)
- wherein R′ has the same meaning as R above, and subsequent hydrolysis.
(R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole free base, in crystalline form.
(R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole free base, in crystalline form, characterized by an XRPD spectrum as shown in FIG. 1, wherein the most intense peaks fall at 9.66, 10.77, 11.10, 12.99, 14.55, 16.56, 17.19, 17.94, 18.72, 21.42, 21.84, 23.49, 24.21, 27.00 and 28.23±0.2° in 2q.
(R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole monohydrate dihydrocloride salt, in crystalline form.
(R)-2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole monohydrate dihydrocloride salt, in crystalline form, characterised by an XRPD spectrum as shown in FIG. 2, wherein the most intense peaks fall at 6.48, 12.06, 12.93, 13.29, 13.92, 15.15, 16.95, 17.25, 17.91, 19.47, 21.36, 24.21, 24.75, 24.99, 25.59 and 28.44±0.2° in 2q;
- and an IR spectrum as shown in FIG. 3, showing the most intense peaks at 3411, 2945, 2742, 2440, 1651, 1627, 1432, 1362, 1218, 1070, 1042, 982, 760 e 714 cm−1.
Dependencies are inferred from the claim text.